Variables | eIF6—low (N, %) | eIF6—high (N, %) | p |
---|---|---|---|
Total | 35(67.3%) | 17 (32.7%) | Â |
Clinical parameters | |||
 Gender |  |  | 1.000 |
  Male | 28 (53.8%) | 14 (26.9%) |  |
  Female | 7 (13.5%) | 3 (5.8%) |  |
 Age ( years) |  |  | 0.854 |
  < 60 | 21 (40.4%) | 9 (17.3%) |  |
  ≥ 60 | 14 (26.9%) | 8 (15.4%) |  |
 Differential |  |  | 0.662 |
  Poorly | 14 (26.9%) | 5 (9.6%) |  |
  High/Moderately | 21 (40.4%) | 12 (23.1%) |  |
 Lymph node metastasis |  |  | 1.000 |
  Negative | 20 (38.5%) | 9 (17.3%) |  |
  Positive | 15 (28.8%) | 8 (15.4%) |  |
 p Stage |  |  | 0.098 |
  1 | 12 (23.1%) | 1 (1.9%) |  |
  2 | 5 (9.6%) | 4 (7.7%) |  |
  3 | 18 (34.6%) | 12 (23.1%) |  |
PET metabolic parameters | (median) | Â | Â |
 SUVmax |  |  | 0.010* |
  Low | 21 (40.4%) | 3 (5.8%) |  |
  High | 14 (26.9%) | 14 (26.9%) |  |
 SUVmean |  |  | 0.018* |
  Low | 22 (42.3%) | 4 (7.7%) |  |
  High | 13 (25%) | 13 (25%) |  |
 TLG |  |  | 0.237 |
  Low | 20 (38.5%) | 6 (11.5%) |  |
  High | 15 (28.8%) | 11 (21.2%) |  |
 MTV |  |  | 1.000 |
  Low | 18 (34.6%) | 8 (15.4%) |  |
  High | 17 (32.7%) | 9 (17.3%) |  |